J. Watters

发表

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

D. Bergstrom, Weidong Zhang, C. Dib, 2015, Cancer research.

EMT is the dominant program in human colon cancer

David B Jackson, David B. Jackson, T. Yeatman, 2011, BMC Medical Genomics.

Comparative expression pathway analysis of human and canine mammary tumors

J. Castle, G. Ciliberto, A. Kulkarni, 2009, BMC Genomics.

Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System

Afshin Mashadi-Hossein, Afshin Mashadi-Hossein, G. Geiss, 2009, BMC Research Notes.

Genome-wide discovery of loci influencing chemotherapy cytotoxicity.

Aldi Kraja, Howard L McLeod, Michael A Province, 2004, Proceedings of the National Academy of Sciences of the United States of America.

A mouse-based strategy for cyclophosphamide pharmacogenomic discovery.

Howard L McLeod, J. Watters, H. McLeod, 2003, Journal of applied physiology.

Analysis of variation in mouse TPMT genotype, expression and activity.

J. Watters, H. McLeod, Wanghai Zhang, 2004, Pharmacogenetics.

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context

Marc Ferrer, Michelle A Cleary, Michael D Altman, 2016, Journal of biomolecular screening.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010, BMC Medical Genomics.

Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry.

J. Watters, H. McLeod, W. Hou, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cancer pharmacogenomics: current and future applications.

Howard L McLeod, J. Watters, H. McLeod, 2003, Biochimica et biophysica acta.

Using genome-wide mapping in the mouse to identify genes that influence drug response.

J. Watters, H. McLeod, 2003, TIPS - Trends in Pharmacological Sciences.

Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.

J. Watters, H. McLeod, 2002, Pharmacogenomics.

Inverse relationship between matrix remodeling and lipid metabolism during osteoarthritis progression in the STR/Ort mouse.

Robert L. Phillips, L. Duong, J. Watters, 2007, Arthritis and rheumatism.

Developing gene expression signatures of pathway deregulation in tumors

C. J. Roberts, J. Watters, James W Watters, 2006, Molecular Cancer Therapeutics.

An accessible pharmacodynamic transcriptional biomarker for notch target engagement

J. Lunceford, J. Watters, A. Loboda, 2016, Clinical pharmacology and therapeutics.

Experimental Therapeutics, Molecular Targets, and Chemical Biology De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

P. Majumder, J. Watters, C. Winter, 2009 .

Can phenotypic pathway signatures improve the prediction of response to PI3K pathway inhibitors

J. Watters, Pearl S Huang, 2009 .

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

A. Maitra, M. Hidalgo, J. Watters, 2011, Clinical Cancer Research.

Irinotecan pharmacogenetics: is it time to intervene?

J. Watters, H. McLeod, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity.

Shaomeng Wang, J. Watters, C. García-echeverría, 2012 .

Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting

Justin Guinney, Hongyue Dai, Eric E. Schadt, 2011, PloS one.

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

Robert Beckman, Santosh Kesari, Ian Krop, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Candidate gene selection in pharmacogenomics: biology leads the way.

J. Watters, H. McLeod, 2004, Pharmacogenomics.

A top‐down, step up approach to pharmacogenetic discovery using CEPH family cell lines

A. Kraja, J. Watters, H. McLeod, 2005 .

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Aaron J. Johnson, J. Sarkaria, J. Watters, 2018, Molecular Cancer Therapeutics.

Regulation of the O2-Evolving Mechanism during N2-Fixation in the Diazotrophic Cyanobacterium Cyanothece sp. ATCC 51142

J. Watters, L. Sherman, M. Colón-López, 1995 .

CEPH individuals are representative of the European American population: implications for pharmacogenetics.

J. Watters, H. McLeod, S. Marsh, 2005, Pharmacogenomics.

Abstract 26: Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K, andWntpathway genes in plucked human hair follicles

A. Podtelezhnikov, D. Bergstrom, R. Railkar, 2010 .

Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11

J. Watters, W. Dietrich, J. Ballard, 1998, Molecular microbiology.

Procedures for the Isolation of Cyanobacterial Random Mutants with a Digital Imaging Spectrophotometer

J. Watters, L. Sherman, P. Meunier, 1997, Plant Molecular Biology Reporter.

Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor

Ken Dewar, Jessica Lehoczky, K. Dewar, 2001, Current Biology.

Genetic, physical, and transcript map of the Ltxs1 region of mouse chromosome 11.

J. Watters, W. Dietrich, 2001, Genomics.

Abstract A226: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line.

D. Bergstrom, J. Watters, J. Pollard, 2011 .

Pharmacogenomics: the influence of genomic variation on drug response.

J. Watters, H. McLeod, F. Thomas, 2004, Current topics in medicinal chemistry.

Irinotecan Pharmacogenetics: Is It Time

J. Watters, H. McLeod, 2004 .

Experimental Therapeutics, Molecular Targets, and Chemical Biology De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

P. Majumder, J. Watters, C. Winter, 2009 .

Recent advances in the pharmacogenetics of cancer chemotherapy.

J. Watters, H. McLeod, 2002, Current opinion in molecular therapeutics (Print).

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

D. Bergstrom, Weidong Zhang, C. Dib, 2015, Cancer research.

Using genetic variation to optimize cancer chemotherapy.

J. Watters, H. McLeod, C. Papageorgio, 2003, Clinical advances in hematology & oncology : H&O.

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .